Search Videos by Topic or Participant
Browse by Series:

Role of NOTCH1 Mutations in CLL

Panelists: Myron S. Czuczman, MD, Roswell Park; John C. Byrd, MD, Ohio State;Richard Furman, MD, Weill Cornell; Thomas J. Kipps, MD, UCSD; Shuo
Published: Wednesday, Mar 18, 2015
For High-Definition, Click
Deep genomic sequencing has identified recurrent mutations in the NOTCH1 proto-oncogene in approximately 5% to 10% of patients with chronic lymphocytic leukemia (CLL), explains Thomas J. Kipps, MD. Mutations in the NOTCH1 gene have been associated with rapid disease progression and inferior survival in patients with CLL.

In the CLL 8 trial of the German CLL group, the addition of rituximab to fludarabine plus cyclophosphamide did not demonstrate an improvement in progression-free survival in patients with a NOTCH1 mutation. These findings suggest that NOTCH1 could predict a lack of benefit with rituximab. However, research will need to confirm whether this observation holds true with other CD20 inhibitors.

Although not yet confirmed, NOTCH1 appears to downregulate CD20, reducing the probability of response to anti-CD20 monoclonal antibodies, Kipps suggests. Clinical studies are currently assessing the role of NOTCH1 mutations on resistance to therapy. Additionally, therapeutic approaches using agents that block NOTCH1 activation or kinase inhibitors that target B-cell receptor signaling are currently in progress. 


Slider Left
Slider Right
For High-Definition, Click
Deep genomic sequencing has identified recurrent mutations in the NOTCH1 proto-oncogene in approximately 5% to 10% of patients with chronic lymphocytic leukemia (CLL), explains Thomas J. Kipps, MD. Mutations in the NOTCH1 gene have been associated with rapid disease progression and inferior survival in patients with CLL.

In the CLL 8 trial of the German CLL group, the addition of rituximab to fludarabine plus cyclophosphamide did not demonstrate an improvement in progression-free survival in patients with a NOTCH1 mutation. These findings suggest that NOTCH1 could predict a lack of benefit with rituximab. However, research will need to confirm whether this observation holds true with other CD20 inhibitors.

Although not yet confirmed, NOTCH1 appears to downregulate CD20, reducing the probability of response to anti-CD20 monoclonal antibodies, Kipps suggests. Clinical studies are currently assessing the role of NOTCH1 mutations on resistance to therapy. Additionally, therapeutic approaches using agents that block NOTCH1 activation or kinase inhibitors that target B-cell receptor signaling are currently in progress. 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x